Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: A prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 4, 2014, Pages 279-288

  Selvin, Elizabeth ^a,b   Rawlings, Andreea M ^a,b   Grams, Morgan ^b   Klein, Ronald ^c   Sharrett, A Richey ^a   Steffes, Michael ^d   Coresh, Josef ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSAMINE; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; GLYCOSYLATED SERUM ALBUMIN; SERUM ALBUMIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INCIDENTAL FINDING; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERFORMANCE MEASUREMENT SYSTEM; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; AGED; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DIAGNOSTIC USE; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY;

AGED; ATHEROSCLEROSIS; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SERUM ALBUMIN;

EID: 84899585626     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70199-2     Document Type: Article

References (39)

1. 1C assay into estimated average glucose values. Diabetes Care 2008, 31:1473-1478.
2. Standards of medical care in diabetes-2010. Diabetes Care 2010, 33(suppl 1):S11-S61. ADA.
3. Colagiuri S, Lee CM, Wong TY, et al. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011, 34:145-150.
4. 1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the US population: implications for diabetes diagnostic thresholds. Diabetes Care 2009, 32:2027-2032.
5. Wong TY, Liew G, Tapp RJ, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 2008, 371:736-743.
6. Davidson MB, Schriger DL, Peters AL, Lorber B Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA 1999, 281:1203-1210.
7. 1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32:1327-1334. International Expert Committee.
8. Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med 2011, 154:303-309.
9. Selvin E, Francis LM, Ballantyne CM, et al. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care 2011, 34:960-967.
10. Juraschek SP, Steffes MW, Miller ER, Selvin E Alternative markers of hyperglycemia and risk of diabetes. Diabetes Care 2012, 35:2265-2270.
11. 1c and fasting glucose. Clin Chem 2012, 58:1648-1655.
12. 1c in diabetes: panacea or pointless?. Diabetes 2013, 62:41-43.
13. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson CM Tests of glycemia in diabetes. Diabetes Care 2003, 26(suppl 1):S106-S108.
14. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol 1989, 129:687-702. The ARIC investigators.
15. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes 2003, 52:1799-1805.
16. Hubbard LD, Brothers RJ, King WN, et al. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the atherosclerosis risk in communities study. Ophthalmology 1999, 106:2269-2280.
17. Couper DJ, Klein R, Hubbard LD, et al. Reliability of retinal photography in the assessment of retinal microvascular characteristics: the Atherosclerosis Risk in Communities Study. Am J Ophthalmol 2002, 133:78-88.
18. 1c from stored whole blood samples in the Atherosclerosis Risk in Communities study. J Diabetes 2010, 2:118-124.
19. Operations manual no 2: cohort component procedures, version 1.0 1987, Anon, ARIC Coordinating Center, School of Public Health, University of North Carolina, Chapel Hill, NC.
20. Operations manual no 11: sitting blood pressure, version 1.0 1987, Anon, ARIC Coordinating Center, School of Public Health, University of North Carolina, Chapel Hill, NC.
21. Operations manual no 10: clinical chemistry determinations, version 1.0 1987, Anon, ARIC Coordinating Center, School of Public Health, University of North Carolina, Chapel Hill, NC.
22. Baecke JA, Burema J, Frijters JE A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982, 36:936-942.
23. Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(suppl 1):S11-S66. ADA.
24. McCance DR, Hanson RL, Charles MA, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994, 308:1323-1328.
25. 1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997, 20:785-791.
26. Harrell FE, Lee KL, Mark DB Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387.
27. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
28. Harrell FE Regression modeling strategies with applications to linear models, logistic regression, and survival analysis 2001, Springer, New York, NY.
29. 1C versus glucose testing: a comparison. Diabetes Care 2011, 34:518-523.
30. 1c measurement. J Diabetes Sci Technol 2009, 3:446-451.
31. Nathan DM, Singer DE, Hurxthal K, Goodson JD The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984, 310:341-346.
32. Shafi T, Sozio SM, Plantinga LC, et al. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care 2013, 36:1522-1533.
33. Fukuoka K, Nakao K, Morimoto H, et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton) 2008, 13:278-283.
34. 1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int 2010, 30:72-79.
35. 1C) values and to retinopathy, nephropathy and cardiovascular outcomes in the DCCT/EDIC study. Diabetes 2013, published online Aug 29. http://dx.doi.org/10.2337/db13-0782.
36. Upton J, Lever M, Sadler WA, George PM, Boswell DR The quality of performance of the fructosamine test. N Z Med J 1988, 101:606-608.
37. Lacher DA, Hughes JP, Carroll MD Estimate of biological variation of laboratory analytes based on the third National Health and Nutrition Examination survey. Clin Chem 2005, 51:450-452.
38. Cohen RM, Sacks DB Comparing multiple measures of glycemia: how to transition from biomarker to diagnostic test?. Clin Chem 2012, 58:1615-1617.
39. Schneider AL, Pankow JS, Heiss G, Selvin E Validity and reliability of self-reported diabetes in the atherosclerosis risk in communities study. Am J Epidemiol 2012, 176:738-743.